Is your cervical dystonia medication wearing off too soon, with the pain returning? You’re not alone.
A Phase 3 global research study called ASPEN, sponsored by Revance, needs people aged 18 to 80 who have been diagnosed with isolated cervical dystonia and who haven’t had a botulinum toxin injection within the previous 14 weeks.
The investigational drug, daxibotulinumtoxinA for injection (also called DAXI for injection), has the potential to manage your cervical dystonia symptoms longer than current forms of botulinum toxin and to have fewer side effects. The results of the Phase 2 study suggest that DAXI for injection is well tolerated and that patients’ symptoms were well managed.
If you are living with isolated cervical dystonia, you may qualify for this research study and receive, at no cost, the investigational drug, study-related care from a local study doctor, and reimbursement for travel expenses. Doctors will also check other requirements to confirm that you qualify for this study.
Research is our greatest hope for continuing to find new treatments – and someday a cure – to help today’s patients and future generations. You can play an important role in the ASPEN study.
To learn more about the ASPEN study and if you may be eligible, visit www.studycd.com